World Neurodiagnostics Market Set to Reach $8.4 Billion by 2024 - Comprehensive Industry Insights, Opportunities and ChallengesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 18 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)World Neurodiagnostics Market Set to Reach $8.4 Billion by 2024 - Comprehensive Industry Insights, Opportunities and ChallengesGlobeNewswireJanuary 10, 2020ReblogShareTweetShareDublin, Jan. 10, 2020 (GLOBE NEWSWIRE) -- The "Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User, and Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.The global neurodiagnostics market is expected to reach USD 8.4 billion by 2024 from USD 5.9 billion in 2019, at a CAGR of 7.3%. The demand for neurodiagnostic products is expected to grow due to the increasing prevalence of neurological disorders & diseases. The neurodiagnostics market is segmented on product, condition, end-user, and region.The hospitals & surgical centers segment accounted for the largest share of the neurodiagnostics market by end-user in 2018.Based on end-user, the neurodiagnostics market is segmented into hospitals & surgical centers, diagnostic laboratories & imaging centers, neurology centers, ambulatory care centers (ACCs), and research laboratories & academic institutes. In 2018, hospitals & surgical centers accounted for the largest share of the neurodiagnostics market due to the financial capabilities of hospitals to purchase expensive equipment, such as neurodiagnostic devices.The neurodegenerative diseases segment accounted for the largest share of the neurodiagnostics market by condition in 2018.The neurodiagnostics market, by condition, is segmented into neurodegenerative diseases, epilepsy, stroke, headache disorders, sleep disorders, and other conditions. In 2019, the neurodegenerative diseases segment is expected to account for the largest share of the neurodiagnostics market due to the increasing incidence of traumatic brain injuries, dementia, Parkinson's disease, and Huntington's disease, and the growing number of neurological examinations for the diagnosis of these conditions.North America accounted for the largest share of the neurodiagnostics market in 2018.North America accounted for the largest share of the neurodiagnostics market in 2018, followed by Europe. This can primarily be attributed to the presence of a highly developed healthcare system, high adoption of innovative neurodiagnostic devices among medical professionals, full availability of advanced neurodiagnostic tools, and the large number of neurodiagnostic devices manufacturing companies that have an established base or are headquartered in the US.Key Topics Covered1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 4.1 Market Overview4.2 Neurodiagnostics Market, By Product, 2019 Vs. 20244.3 Market Share, By End User and Region (2019)4.4 Market, By Condition, 2019 Vs. 2024 (USD Million)4.5 Market, By Country5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Increasing Prevalence of Neurological Diseases & Disorders5.2.1.2 Technological Advancements5.2.1.3 Growing Patient Emphasis on Effective and Early Disease Diagnosis5.2.1.4 Increasing Number of Diagnostic Centers & Hospitals5.2.1.5 Advances in Genomics and Proteomics for the Diagnosis of Neurodegenerative Disorders5.2.2 Restraints5.2.2.1 High Cost of Neurodiagnostic Devices5.2.2.2 Growing Adoption of Refurbished Neurodiagnostic Systems5.2.3 Opportunities5.2.3.1 Increasing Application in Clinical Trials5.2.3.2 Emerging Markets5.2.4 Challenges5.2.4.1 Dearth of Skilled Surgeons6 Neurodiagnostics Market, By Product 6.1 Introduction6.2 Diagnostic Imaging Systems6.2.1 Growing Number of Diagnostic Laboratories & Imaging Centers to Drive the Adoption of Diagnostic Imaging Systems6.2.1.1 MRI Systems6.2.1.2 EEG Systems6.2.1.3 CT Scanners6.2.1.4 PET Scanners6.2.1.5 EMG Devices6.2.1.6 Ultrasound Imaging Systems6.2.1.7 MEG Devices6.2.1.8 Angiography Systems6.2.1.9 Other Diagnostic Imaging Systems6.3 Clinical Diagnostic Instruments6.3.1 Increasing Public-Private Investments are Supporting the Growth of This Market Segment6.3.1.1 PCR Instruments6.3.1.2 NGS Instruments6.3.1.3 Sanger Sequencers6.3.1.4 Other Clinical Diagnostic Instruments6.4 Reagents & Consumables6.4.1 High Consumption of Reagents in Various Routine Assays & Techniques is Driving the Growth of This Segment6.4.1.1 Media & Sera6.4.1.2 Antibodies6.4.1.3 Buffers6.4.1.4 Solvents6.4.1.5 Enzymes, Proteins, & Peptides6.4.1.6 Probes6.4.1.7 Other Reagents & Consumables7 Neurodiagnostics Market, By Condition 7.1 Introduction7.2 Neurodegenerative Diseases7.2.1 Growing Number of Neurological Examinations is Supporting the Growth of This Segment7.3 Stroke7.3.1 Growing Awareness About Strokes & Its Treatment Options in the Market are Supporting Market Growth7.4 Epilepsy7.4.1 Favorable Government Initiatives Have Resulted in the Increased Adoption of Neurodiagnostic Products7.5 Headache Disorders7.5.1 Increasing Incidence of Migraines & Tension Headaches to Support Market Growth7.6 Sleep Disorders7.6.1 Increasing Stress & Unhealthy Lifestyles are Supporting the Growth of This Market Segment8 Neurodiagnostics Market, By End User 8.1 Introduction8.2 Hospitals & Surgical Centers8.2.1 Hospitals & Surgical Centers are the Major End Users of Neurodiagnostic Devices Owing to Their High Purchasing Power to Buy Expensive Equipment8.3 Diagnostic Laboratories & Imaging Centers8.3.1 Growing Number of Private Imaging Centers Supports the Growth of This End-User Segment8.4 Neurology Centers8.4.1 Lower Costs and Shorter Waiting Periods Compared to Hospitals to Drive Market Growth8.5 Ambulatory Care Centers8.5.1 High-Quality and Lower-Cost Services Offered By Ambulatory Care Centers to Drive Market Growth8.6 Research Laboratories & Academic Institutes8.6.1 Budgetary Limitations Faced By Small Research Laboratories & Academic Institutes Will Restrain Market Growth9 Neurodiagnostics Market, By Region 9.1 Introduction9.2 North America9.2.1 US9.2.1.1 US Dominates the Market Due to the Increased Adoption of High-End Neurodiagnostic Systems9.2.2 Canada9.2.2.1 Favorable Environment for R&D in the Field of Neurosciences is Driving Market Growth9.3 Europe9.3.1 Germany9.3.1.1 Germany Commands the Largest Share of the Neurodiagnostics Market in Europe9.3.2 UK9.3.2.1 Market Growth in the UK is Mainly Driven By the Increasing Incidence of Neurodegenerative Diseases9.3.3 France9.3.3.1 Increasing Healthcare Expenditure Coupled With the High-End Medical Infrastructure Will Drive Demand for Neurodiagnostic Devices9.3.4 Italy9.3.4.1 Ongoing Economic Crisis in the Country and Rising Government Pressure to Reduce Healthcare Costs May Slow Market Growth9.3.5 Spain9.3.5.1 Increased Cost Burden on the State-Run Health Insurance System Will Hinder Market Growth9.3.6 Rest of Europe9.4 Asia Pacific9.4.1 Japan9.4.1.1 Favorable Reimbursement and Growing Neurological Disorder Patients Have Propelled Market Growth in Japan9.4.2 China9.4.2.1 Government Initiatives to Modernize Healthcare Facilities and the Rising Geriatric Population Will Drive Market Growth9.4.3 India9.4.3.1 Low Entry Barriers Have Made India a Prominent Market to Invest In9.4.4 Australia9.4.4.1 Technology Advancements and Improving Healthcare Infrastructure Will Drive the Market in Australia9.4.5 South Korea9.4.5.1 Rising Healthcare Spending and Medical Coverage for Neurological Disease Treatment Will Propel the Market Growth9.4.6 Rest of Asia Pacific9.5 Latin America9.5.1 Brazil9.5.1.1 Inadequate Accessibility to Healthcare has Driven the Government to Undertake Corrective Measures9.5.2 Mexico9.5.2.1 Mexico is a Prominent Medical Tourism Hub for US Patients9.5.3 Rest of Latin America9.6 Middle East & Africa9.6.1 Infrastructural Development and Growing Healthcare Expenditure Will Contribute to Market Growth in the MEA10 Competitive Landscape 10.1 Overview10.2 Market Share Analysis10.3 Competitive Scenario10.3.1 Key Product Launches10.3.2 Key Expansions10.3.3 Key Acquisitions10.3.4 Key Partnerships, Agreements, and Collaborations10.4 Competitive Leadership Mapping10.4.1 Visionary Leaders10.4.2 Innovators10.4.3 Dynamic Differentiators10.4.4 Emerging Companies11 Company Profiles 11.1 GE Healthcare11.2 Philips Healthcare11.3 Siemens Healthineers11.4 Hitachi, Ltd.11.5 Canon, Inc.11.6 Lifelines Neuro Company, LLC11.7 Natus Medical Incorporated11.8 F. Hoffmann-La Roche AG11.9 FUJIFILM Holdings Corporation11.10 Mitsar Co. Ltd.11.11 Advanced Brain Monitoring, Inc.11.12 Thermo Fisher Scientific, Inc.11.13 Bio-Rad Laboratories11.14 QIAGEN N.V.11.15 Nihon Kohden Corporation11.16 Other Companies11.16.1 ANT Neuro11.16.2 Fonar Corporation11.16.3 Fujirebio (A Part of Miraca Group)11.16.4 DRG Instruments GmbH11.16.5 Tecan Trading AGStory continuesFor more information about this report visit https://www.researchandmarkets.com/r/v9yhvgResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextLatin America roundup: SoftBank adds $1B, Stori raises $10M and Grow Mobility puts on the brakesTechCrunch4 Giants See Stocks Plummet on Coronavirus WarningsGuruFocus.comTrade Desk Tops Earnings Views, Sets Higher Investments In Internet TVInvestor's Business DailyWalmart’s Answer to Amazon Prime? Walmart+Footwear NewsBudweiser Brewer Shares Dive as It Loses More U.S. Market ShareThe Wall Street JournalBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoCrocs CEO explains its major turnaroundYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoWhat the GM strike means for the U.S. economyYahoo FinanceWhy negative interest rates are 'seriously dangerous': strategistYahoo FinanceAurora Cannabis tumbles after double downgradeYahoo Finance VideoCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoLoan growth will be a 'critical factor' in upcoming bank earnings: AnalystYahoo Finance Video